Accumulation of (123)I-Ioflupane Is a Useful Marker of the Efficacy of Selegiline Monotherapy in Drug-Naïve Parkinson’s Disease

Background: Selegiline enhances the patient’s endogenous dopamine by inhibiting dopamine metabolism. The efficacy of selegiline monotherapy for drug-naïve Parkinson’s disease (PD) patients may depend on the degree of dopaminergic neuronal degeneration. (123)I-Ioflupane single photon emission compute...

Descripción completa

Detalles Bibliográficos
Autores principales: Murakami, Hidetomo, Nohara, Tetsuhito, Uchiyama, Masanobu, Owan, Yoshiyuki, Futamura, Akinori, Shiromaru, Azusa, Tsukada, Setsuro, Saito, Yu, Kuroda, Takeshi, Yano, Satoshi, Ishigaki, Seiichiro, Katoh, Hirotaka, Munechika, Jiro, Ohgiya, Yoshimitsu, Gokan, Takehiko, Ono, Kenjiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626819/
https://www.ncbi.nlm.nih.gov/pubmed/29033831
http://dx.doi.org/10.3389/fnagi.2017.00321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626819/
https://www.ncbi.nlm.nih.gov/pubmed/29033831
http://dx.doi.org/10.3389/fnagi.2017.00321

Ejemplares similares